ArticlePloS one2025
Global, regional, and national burdens of late-onset epilepsy in adults aged 65 years and older from 1990 to 2021: A population-based study.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Aging, the microbiota-gut-brain axis, and late-life epilepsy: a hypothesis-driven review.Frontiers in molecular neuroscience · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveEpilepsy remains one of the most widespread and severe neurological disorders worldwide. This study aims to evaluate the burden of late-onset epilepsy (LOE) and investigate its temporal trends and inequalities among older adults at global, regional, and national scales between 1990 and 2021.
methodsThis analysis utilizes data from the 2021 Global Burden of Diseases, Injuries, and Risk Factors Study (GBD). Temporal trends in the age-standardized prevalence rate (ASPR), incidence rate (ASIR), mortality rate (ASMR), and disability-adjusted life years (DALYs) rate for LOE were quantified through the calculation of average annual percentage change over the study period.
resultsIn 2021, the global ASPR and ASIR of LOE in adults aged 65 and older were estimated at 472.74 (95% UI: 332.21 to 654.96) and 33.12 (95% UI: 18.68 to 50.29) per 100,000 population, respectively. The global ASMR was 4.76 per 100,000 population (95% UI: 3.80 to 5.26), while the age-standardized DALYs rate reached 189.08 per 100,000 population (95% UI: 137.47 to 259.90). Among the five sociodemographic index (SDI) regions, high-SDI areas exhibited the greatest ASPR, ASIR, ASMR, and age-standardized DALY rate, whereas high-middle SDI regions reported the lowest. Geospatially, Andean Latin America recorded the highest ASPR, while Western Europe reported the highest ASIR. The highest ASMR and age-standardized DALY rate were observed in Central and Eastern Sub-Saharan Africa, respectively. Among 204 countries, Equatorial Guinea displayed the highest ASPR, while Germany had the highest ASIR. Notably, Zambia exhibited both the highest ASMR and age-standardized DALY rate for LOE. However, the inequalities associated with the SDI across countries gradually diminished over time.
conclusionsThe study suggest that regions with high SDI continued to experience elevated ASPR, ASIR, ASMR, and age-standardized DALY rates. These findings highlight the importance of integrating LOE care into health systems, particularly for adults aged 65 years and older.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.